Ionis Financial Statements From 2010 to 2024

IONS Stock  USD 40.68  0.13  0.32%   
Ionis Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Ionis Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Ionis Pharmaceuticals financial statements helps investors assess Ionis Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ionis Pharmaceuticals' valuation are summarized below:
Gross Profit
-257.9 M
Profit Margin
(0.47)
Market Capitalization
5.9 B
Enterprise Value Revenue
6.6114
Revenue
787.6 M
There are over one hundred nineteen available fundamental trends for Ionis Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should confirm Ionis Pharmaceuticals' regular fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 6.8 B in 2024. Enterprise Value is likely to gain to about 7.8 B in 2024

Ionis Pharmaceuticals Total Revenue

827.03 Million

Check Ionis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ionis main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.6 M, Interest Expense of 79.4 M or Total Revenue of 827 M, as well as many exotic indicators such as Price To Sales Ratio of 15.6, Dividend Yield of 0.0 or PTB Ratio of 17.8. Ionis financial statements analysis is a perfect complement when working with Ionis Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Ionis Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Ionis Pharmaceuticals Technical models . Check out the analysis of Ionis Pharmaceuticals Correlation against competitors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

Ionis Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.1 BB1.7 B
Slightly volatile
Short and Long Term Debt Total1.5 B1.5 B655.6 M
Slightly volatile
Total Current Liabilities470.5 M448.1 M212.5 M
Slightly volatile
Total Stockholder Equity265.7 M386.7 M465.5 M
Slightly volatile
Property Plant And Equipment Net255.1 M242.9 M137.9 M
Slightly volatile
Cash534.5 M399.3 M1.1 B
Slightly volatile
Non Current Assets Total365.6 M348.2 M227.4 M
Slightly volatile
Non Currrent Assets Other34.5 M62.3 M65.5 M
Pretty Stable
Cash And Short Term Investments2.4 B2.3 B1.3 B
Slightly volatile
Common Stock Shares Outstanding83.9 M143.2 M115.2 M
Slightly volatile
Liabilities And Stockholders Equity3.1 BB1.7 B
Slightly volatile
Non Current Liabilities Total2.3 B2.2 B989.6 M
Slightly volatile
Other Current Assets193.7 M184.4 M91.9 M
Slightly volatile
Other Stockholder Equity2.3 B2.2 B1.6 B
Slightly volatile
Total Liabilities2.7 B2.6 B1.2 B
Slightly volatile
Total Current Assets2.8 B2.6 B1.5 B
Slightly volatile
Short Term Debt55.8 M53.2 M30.4 M
Slightly volatile
Intangible Assets24.2 M33.4 M22.4 M
Slightly volatile
Accounts Payable27.3 M26 M17.9 M
Slightly volatile
Net Receivables102.7 M97.8 M45.7 M
Slightly volatile
Property Plant And Equipment Gross356.7 M339.7 M158.9 M
Slightly volatile
Short Term InvestmentsB1.9 B894.4 M
Slightly volatile
Other Assets57.3 M40.2 M79.6 M
Slightly volatile
Long Term Debt1.3 B1.2 B636.8 M
Slightly volatile
Common Stock Total Equity110.1 K163.3 K121.2 K
Slightly volatile
Property Plant Equipment79.6 M85.4 M105 M
Slightly volatile
Other Liabilities170 M330.9 M222.3 M
Slightly volatile
Current Deferred Revenue158.7 M151.1 M87.2 M
Slightly volatile
Inventory29.8 M28.4 M14.3 M
Slightly volatile
Net Tangible Assets531.9 M658.8 M498.5 M
Slightly volatile
Long Term Debt Total1.4 B1.4 B646.6 M
Slightly volatile
Capital Surpluse1.7 B2.4 B1.6 B
Slightly volatile
Deferred Long Term Liabilities96.7 M83.6 M83.1 M
Very volatile
Non Current Liabilities Other261.3 M513.7 M206.6 M
Slightly volatile
Short and Long Term Debt43.5 M53.2 M30 M
Slightly volatile
Net Invested Capital1.9 B1.7 B1.4 B
Slightly volatile
Net Working Capital2.1 B2.2 B1.4 B
Slightly volatile
Capital Stock154.9 K144 K140.3 K
Slightly volatile
Deferred Long Term Asset Charges232.6 M261.7 M285 M
Slightly volatile
Long Term InvestmentsMM9.8 M
Slightly volatile

Ionis Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue827 M787.6 M477.7 M
Slightly volatile
Other Operating Expenses1.2 B1.1 B569.4 M
Slightly volatile
Cost Of Revenue8.7 M9.1 M113.7 M
Slightly volatile
Total Operating Expenses1.2 B1.1 B565 M
Slightly volatile
Research Development944.6 M899.6 M436.3 M
Slightly volatile
Selling General Administrative244.2 M232.6 M131.7 M
Slightly volatile
Selling And Marketing Expenses764.8 K805 K11.5 M
Slightly volatile
Non Operating Income Net Other193.6 M184.4 M47 M
Slightly volatile
Interest Income2.9 M3.1 M11.8 M
Slightly volatile
Reconciled Depreciation18.6 M22.5 M13 M
Slightly volatile

Ionis Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow154.8 M276.5 M237.9 M
Slightly volatile
Depreciation23.6 M22.5 M13.6 M
Slightly volatile
Capital Expenditures29.4 M28 M19.1 M
Slightly volatile
End Period Cash Flow419.2 M399.3 M281.8 M
Slightly volatile
Stock Based Compensation58.6 M105.8 M78.4 M
Slightly volatile
Issuance Of Capital Stock8.6 MM299.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio15.69.19715.8673
Slightly volatile
PTB Ratio17.818.733518.3089
Pretty Stable
Days Sales Outstanding43.0545.3109183
Slightly volatile
Book Value Per Share2.122.70053.5595
Slightly volatile
Invested Capital6.463.7591.9812
Slightly volatile
Stock Based Compensation To Revenue0.10.13430.1533
Slightly volatile
PB Ratio17.818.733518.3089
Pretty Stable
EV To Sales15.5210.535514.8283
Slightly volatile
Inventory Turnover0.310.321318.128
Slightly volatile
Days Of Inventory On Hand1.2 K1.1 K525
Slightly volatile
Payables Turnover0.330.35097.7876
Slightly volatile
Sales General And Administrative To Revenue0.160.29530.2141
Slightly volatile
Research And Ddevelopement To Revenue1.681.14221.1924
Slightly volatile
Cash Per Share17.0916.280514.4369
Slightly volatile
Days Payables Outstanding1.1 KK730
Slightly volatile
Intangibles To Total Assets0.01210.01280.0188
Slightly volatile
Current Ratio4.445.89586.3712
Slightly volatile
Tangible Book Value Per Share1.972.70053.6314
Slightly volatile
Receivables Turnover7.658.055529.3419
Slightly volatile
Graham Number13.0912.46729.4078
Slightly volatile
Shareholders Equity Per Share2.122.70053.5595
Slightly volatile
Debt To Equity6.463.7591.9812
Slightly volatile
Revenue Per Share5.785.50073.5834
Slightly volatile
Interest Debt Per Share11.2110.67915.3209
Slightly volatile
Debt To Assets0.340.48610.3761
Slightly volatile
Operating Cycle1.2 K1.2 K705
Pretty Stable
Price Book Value Ratio17.818.733518.3089
Pretty Stable
Days Of Payables Outstanding1.1 KK730
Slightly volatile
Company Equity Multiplier7.357.73264.1786
Slightly volatile
Long Term Debt To Capitalization0.440.78360.534
Pretty Stable
Total Debt To Capitalization0.450.78990.5473
Pretty Stable
Debt Equity Ratio6.463.7591.9812
Slightly volatile
Quick Ratio4.715.42078.2651
Slightly volatile
Cash Ratio0.850.8914.9928
Pretty Stable
Days Of Inventory Outstanding1.2 K1.1 K525
Slightly volatile
Days Of Sales Outstanding43.0545.3109183
Slightly volatile
Price To Book Ratio17.818.733518.3089
Pretty Stable
Fixed Asset Turnover2.233.24223.076
Slightly volatile
Debt Ratio0.340.48610.3761
Slightly volatile
Price Sales Ratio15.69.19715.8673
Slightly volatile
Asset Turnover0.180.26340.2785
Pretty Stable
Price Fair Value17.818.733518.3089
Pretty Stable

Ionis Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.8 B6.5 BB
Slightly volatile
Enterprise Value7.8 B7.5 B6.8 B
Slightly volatile

Ionis Fundamental Market Drivers

Forward Price Earnings90.9091
Cash And Short Term Investments2.3 B

Ionis Upcoming Events

28th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ionis Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Ionis Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Ionis Pharmaceuticals investors use historical funamental indicators, such as Ionis Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ionis Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Ionis Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ionis Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Ionis Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Ionis Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue151.1 M158.7 M
Total Revenue787.6 M827 M
Cost Of Revenue9.1 M8.7 M
Stock Based Compensation To Revenue 0.13  0.10 
Sales General And Administrative To Revenue 0.30  0.16 
Research And Ddevelopement To Revenue 1.14  1.68 
Capex To Revenue(0.04)(0.04)
Revenue Per Share 5.50  5.78 
Ebit Per Revenue(0.45)(0.47)

Ionis Pharmaceuticals Investors Sentiment

The influence of Ionis Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Ionis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Ionis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ionis. The trend in average sentiment can be used to explain how an investor holding Ionis can time the market purely based on public headlines and social activities around Ionis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ionis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ionis Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Ionis Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Ionis Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ionis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ionis Pharmaceuticals' short interest history, or implied volatility extrapolated from Ionis Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Ionis Pharmaceuticals is a strong investment it is important to analyze Ionis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ionis Pharmaceuticals' future performance. For an informed investment choice regarding Ionis Stock, refer to the following important reports:
Check out the analysis of Ionis Pharmaceuticals Correlation against competitors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Ionis Stock analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.44)
Earnings Share
(2.56)
Revenue Per Share
5.501
Quarterly Revenue Growth
1.136
Return On Assets
(0.08)
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.